| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Clinical and Molecular Hepatology Search > Browse Articles > Search



Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B
Kwan Sik Lee, Young-Oh Kweon, Soon-Ho Um, Byung-Ho Kim, Young Suk Lim, Seung Woon Paik, Jeong Heo, Heon-Ju Lee, Dong Joon Kim, Tae Hun Kim, Young-Sok Lee, Kwan Soo Byun, Daeghon Kim, Myung Seok Lee, Kyungha Yu, Dong Jin Suh
Clin Mol Hepatol.2017;23(4):331-339.   Published online September 26, 2017     
DOI: https://doi.org/10.3350/cmh.2016.0040
                                 Cited By 2
Lamivudine: fading into the mists of time
Jonggi Choi, Young-Suk Lim
Clin Mol Hepatol.2017;23(4):314-315.   Published online November 28, 2017     
DOI: https://doi.org/10.3350/cmh.2017.0110
                              
Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?
Joon Yeul Nam, Jeong-Hoon Lee
Clin Mol Hepatol.2017;23(4):311-313.   Published online December 4, 2017     
DOI: https://doi.org/10.3350/cmh.2017.0069
                              
Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
Hee-Jeong Jeon, Seok Won Jung, Neung Hwa Park, Yujin Yang, Jin-Hee Noh, Jae-Sung Ahn, Hyung Rae Kim, Jae Ho Lee, Jung Woo Shin
Clin Mol Hepatol.2017;23(3):230-238.   Published online June 30, 2017     
DOI: https://doi.org/10.3350/cmh.2017.0003
                                 Cited By 4
Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?
Byung-Cheol Song
Clin Mol Hepatol.2016;22(4):439-442.   Published online December 25, 2016     
DOI: https://doi.org/10.3350/cmh.2016.0108
                              
The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
Jeong Han Kim, Sung Hyun Ahn, Soon Young Ko, Won Hyeok Choe, Kyun-Hwan Kim, So Young Kwon
Clin Mol Hepatol.2016;22(2):241-249.   Published online June 15, 2016     
DOI: https://doi.org/10.3350/cmh.2015.0053
                                 Cited By 3
Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
Chan Ho Park, Seok Won Jung, Jung Woo Shin, Mi Ae Bae, Yoon Im Lee, Yong Tae Park, Hwa Sik Chung, Neung Hwa Park
Clin Mol Hepatol.2016;22(1):152-159.   Published online March 28, 2016     
DOI: https://doi.org/10.3350/cmh.2016.22.1.152
                              
Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
Jung Gil Park, Soo Young Park
Clin Mol Hepatol.2015;21(3):242-248.   Published online September 30, 2015     
DOI: https://doi.org/10.3350/cmh.2015.21.3.242
                                 Cited By 1
Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients
Joo An Hwang, Kee Bum Kim, Min Jae Yang, Sun Gyo Lim, Jae Chul Hwang, Jae Youn Cheong, Sung Won Cho, Soon Sun Kim
Clin Mol Hepatol.2015;21(2):131-140.   Published online June 26, 2015     
DOI: https://doi.org/10.3350/cmh.2015.21.2.131
                                 Cited By 2
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
Sang Kyung Jung, Kyung-Ah Kim, So Young Ha, Hyun Kyo Lee, Young Doo Kim, Bu Hyun Lee, Woo Hyun Paik, Jong Wook Kim, Won Ki Bae, Nam-Hoon Kim, June Sung Lee, Yoon Jung Jwa
Clin Mol Hepatol.2015;21(1):41-48.   Published online March 25, 2015     
DOI: https://doi.org/10.3350/cmh.2015.21.1.41
                                 Cited By 8
Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B
Jeong Han Kim, Hee Won Moon, Soon Young Ko, Won Hyeok Choe, So Young Kwon
Clin Mol Hepatol.2014;20(3):274-282.   Published online September 25, 2014     
DOI: https://doi.org/10.3350/cmh.2014.20.3.274
                                 Cited By 1
Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir
EunYoung Ze, Eun Kyung Baek, Jong Jin Lee, Han Wook Chung, Dae Geon Ahn, Hwan Jun Cho, Jae Cheol Kwon, Hyung Joon Kim, HyunWoong Lee
Clin Mol Hepatol.2014;20(3):267-273.   Published online September 25, 2014     
DOI: https://doi.org/10.3350/cmh.2014.20.3.267
                                 Cited By 5
Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus
Hyun Young Woo, Jong Young Choi, Seung Kew Yoon, Dong Jin Suh, Seung Woon Paik, Kwang Hyub Han, Soon Ho Um, Byung Ik Kim, Heon Ju Lee, Mong Cho, Chun Kyon Lee, Dong Joon Kim, Jae Seok Hwang
Clin Mol Hepatol.2014;20(2):168-176.   Published online June 30, 2014     
DOI: https://doi.org/10.3350/cmh.2014.20.2.168
                                 Cited By 1
HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data
Jeong Han Kim, Yun Jung Choi, Hee Won Moon, Soon Young Ko, Won Hyeok Choe, So Young Kwon
Clin Mol Hepatol.2013;19(4):409-416.   Published online December 28, 2013     
DOI: https://doi.org/10.3350/cmh.2013.19.4.409
                                 Cited By 4
Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients
Jeong Han Kim, Soon Young Ko, Won Hyeok Choe, So Young Kwon, Chang Hong Lee
Clin Mol Hepatol.2013;19(3):273-279.   Published online September 30, 2013     
DOI: https://doi.org/10.3350/cmh.2013.19.3.273
                                 Cited By 1
Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients
Young Kul Jung, Jong Eun Yeon, Kwang Gyun Lee, Eun Seok Jung, Jeong Han Kim, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Sun Ho Um, Ho Sang Ryu, Kwan Soo Byun
Korean J Hepatol.2011;17(4):261-267.   Published online December 26, 2011     
DOI: https://doi.org/10.3350/kjhep.2011.17.4.261
                                 Cited By 6
Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study
George KK Lau, Nancy Leung
Korean J Hepatol.2010;16(3):315-320.   Published online September 30, 2010     
DOI: https://doi.org/10.3350/kjhep.2010.16.3.315
                                 Cited By 9
Efficacy of 48-week clevudine therapy for chronic hepatitis B
Min Hwan Kim, M.D., Kyung-Ah Kim, M.D., June Sung Lee, M.D., Hyun Woong Lee, M.D.1, Hyung Joon Kim, M.D.1, Sang Gu Yun, M.D., Nam-Hoon Kim, M.D., Won Ki Bae, M.D., Young Soo Moon, M.D.
Korean J Hepatol.2009;15(3):331-337.   Published online September 30, 2009     
DOI: https://doi.org/10.3350/kjhep.2009.15.3.331
         Cited By 8
Long-term clevudine therapy in nucleos(t)ide-naive and Lamivudine-experienced patients with hepatitis B virus-related chronic Liver diseases
Heon Ju Lee, M.D., Jong Ryul Eun, M.D., Chang Hyeong Lee, M.D.1, Jae Seok Hwang, M.D.2, Jeong Ill Suh, M.D.3, Byung Seok Kim, M.D.1, Byoung Kuk Jang, M.D.2 Departments of
Korean J Hepatol.2009;15(2):179-192.   Published online June 30, 2009     
DOI: https://doi.org/10.3350/kjhep.2009.15.2.179
         Cited By 12
Comparison of Lamivudine-induced HBsAg Loss rate according to age in children with chronic hepatitis B
Jung Mi Kim , Byung Ho Choe , Mi Ae Chu , Seung Man Cho
Korean J Hepatol.2009;15(2):168-178.   Published online June 30, 2009     
DOI: https://doi.org/10.3350/kjhep.2009.15.2.168
         Cited By 2
Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, Lamivudine-resistant chronic hepatitis B patients
Hyun Wook Jung , Moon Seok Choi , Kap Hyun Kim , Sung Hyun Park , Keum Yeon Kwak , Joon Hyoek Lee , Kwang Cheol Koh , Seung Woon Paik , Byung Chul Yoo
Korean J Hepatol.2009;15(1):52-58.   Published online March 31, 2009     
DOI: https://doi.org/10.3350/kjhep.2009.15.1.52
      
A case report of treatment with pegylated interferon alpha for Lamivudine-resistant chronic hepatitis B virus infection
Won Haing Hur , Hyun Young Woo , Soung Won Jeong , Chan Ran You , Si Hyun Bae , Jong Young Choi , Seung Kew Yoon
Korean J Hepatol.2008;14(4):513-518.   Published online December 31, 2008     
DOI: https://doi.org/10.3350/kjhep.2008.14.4.513
      
The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with Lamivudine-resistant chronic hepatitis B infection
Jae Hyeon Moon , Mong Cho , Ki Tae Yoon , Jung Ho Bae , Jeong Heo , Gwang Ha Kim , Dae Hwan Kang , Geun Am Song
Korean J Hepatol.2008;14(4):503-512.   Published online December 31, 2008     
DOI: https://doi.org/10.3350/kjhep.2008.14.4.503
         Cited By 2
The Korean Journal of Entecavir 1 mg therapy for Lamivudine-refractory chronic hepatitis B
Hyung Joon Kim
Korean J Hepatol.2008;14(3):411-416.   Published online September 30, 2008     
DOI: https://doi.org/10.3350/kjhep.2008.14.3.411
      
The Korean Journal of Adefovir plus Lamivudine combination therapy in Lamivudine-resistant chronic hepatitis B
So Young Kwon
Korean J Hepatol.2008;14(2):235-239.   Published online June 20, 2008     
DOI: https://doi.org/10.3350/kjhep.2008.14.2.235
      
Hepatitis B core antigen expression pattern predicts response to Lamivudine therapy in patients with chronic hepatitis B
Kyeh Dong Shi, M.D., Seong Gyu Hwang, M.D., Ju Hyun Choi, M.D., Il Joon Hwang, M.D., Jai Ho Yoon, M.D., Kwang Il Kim, M.D.1, Chang-Il Kwon, M.D., Sung Pyo Hong, M.D., Pil Won Park, M.D., Kyu Sung Rim, M.D.
Korean J Hepatol.2008;14(2):197-205.   Published online June 20, 2008     
DOI: https://doi.org/10.3350/kjhep.2008.14.2.197
         Cited By 2
Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients
Jin Hee Cho, M.D., Jae Youn Cheong, M.D., Joon Koo Kang, M.D., Jin Sun Park, M.D., Myoung Hee Lee, M.D., Nam Kyu Lim, M.D., Sun Pyo Hong, PhD.1, Soo-Ok Kim, PhD.1, Wang Don Yoo, PhD.1, and Sung Won Cho, M.D.
Korean J Hepatol.2008;14(1):58-66.   Published online March 20, 2008     
DOI: https://doi.org/10.3350/kjhep.2008.14.1.58
         Cited By 1
Change of HBV DNA Level as a Predictor of HBeAg Loss after Lamivudine Treatment
Jae Kwon Jung, M.D., Chang Hyeong Lee, M.D., Eun Young Kim, M.D., Jin Tae Jung, M.D., Joon Hyuck Choi, M.D., Ji Min Han, M.D., Myoung In Jin, M.D., Ju Yeon Cho, M.D., Byung Seok Kim, M.D., Im Hee Shin, Ph.D.1
Korean J Hepatol.2007;13(4):513-520.   Published online December 20, 2007     
DOI: https://doi.org/10.3350/kjhep.2007.13.4.513
      
Effect of Initial Virologic Response to Adefovir on the Development of Resistance to Adefovir in Lamivudine-resistant Chronic Hepatitis B
In Hee Kim , Seong Hun Kim , Hyun Chul Kim , Kyoung Deok Shin , Sang Wook Kim , Seong Ok Lee , Soo Teik Lee , Dae Ghon Kim
Korean J Hepatol.2007;13(3):349-362.   Published online September 20, 2007     
DOI: https://doi.org/10.3350/kjhep.2007.13.3.349
         Cited By 1
Predictors of Lamivudine Resistance in Patients with Chronic Hepatitis B Virus Infection
Jeong Heo , Mong Cho , Byung Mann Cho , Sun Mi Lee , Tae Oh Kim , Gwang Ha Kim , Dae Hwan Kang , Geun Am Song
Korean J Hepatol.2007;13(2):157-165.
      
1 | 2 | 3 |
E-Submission
Email Alert
Author's Index
EndNote Style file download
The Korean Association for the Study of the Liver
The Liver Week 2019
SCImago Journal & Country Rank
PubMed Central
PubMed
Scopus
KoreaMed
KoMCI
ScienceCentral
DOAJ
GoogleScholar
Similarity Check
Crossref Cited-by Linking
CrossMark
Funder Registry
ORCID
MeSH on Demand
COPE
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association for the Study of the Liver. All rights reserved.         
COUNTER
TODAY : 157
TOTAL : 212957